Acute myeloid leukaemia: prognosis and cytogenetic risk
What it is
Prognosis in acute myeloid leukemia is read first from the achievement of first remission. It is achieved in 70-80% if 60 yr old or less, and in 50% if over 60. Median survival is 12-24 months.
Causes and risk
Prognosis is most related to cytogenetics and/or molecular abnormalities, and these sort into three groups:
- Favorable: t(8;21), inv(16), t(16;16), t(15;17), mutated NPM1, biallelic mutated CEBPA
- Intermediate: t(9;11), mutated NPM1 with FLT3-ITD
- Adverse: t(6;9), t(v;11), t(9;22), inv(3), mutated RUNX1, mutated ASXL1, mutated TP53
NPM1 appears in two of the three groups, so it is not read alone: mutated NPM1 by itself is favorable, while mutated NPM1 with FLT3-ITD is intermediate.